Virtual Realityon Pain, Anxiety and Comfort During Trigger Point Injection

Sponsor
Izmir Bakircay University (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT06140368
Collaborator
(none)
100
1
2
7
14.2

Study Details

Study Description

Brief Summary

To determine the effects of virtual reality application during trigger point injection on patients' pain, anxiety and comfort levels.This research was planned as a randomized controlled experimental type. The population of the research was planned to include patients who applied to the Algology polyclinic for trigger point injection. The sample of the research will consist of 150 patients who meet the sampling criteria and agree to participate in the research.Inclusion criteria: Trigger point injection applied for the first time, 18 years and over, understand and speak Turkish, understand verbal and written information given.Patients will be divided into two groups: experimental (virtual reality) and control groups.Data will be collected with the Case Report Form, State Anxiety Scale, General Comfort Scale and Visual Analog Scale.Patients' anxiety, comfort and pain levels will be evaluated before and after trigger point injection.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: virtual reality
N/A

Detailed Description

Patients in the experimental group will be shown videos that the patient wants to watch, such as nature and seaside walks, underwater videos, with music background, through virtual reality glasses for 10 minutes.Patients in the control group will continue routine practice.Patients' anxiety, comfort and pain levels will be evaluated before and after trigger point injection.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Care Provider)
Primary Purpose:
Supportive Care
Official Title:
The Effect of Virtual Reality on Pain, Anxiety and Patient Comfort During Trigger Point Injection
Actual Study Start Date :
May 10, 2023
Actual Primary Completion Date :
Aug 10, 2023
Anticipated Study Completion Date :
Dec 10, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental group

During the trigger point injection, patients will be shown videos that the patient wants to watch, such as nature and seaside walks, underwater videos, with music background, through virtual reality glasses for 10 minutes.

Behavioral: virtual reality
During the trigger point injection, patients will be shown videos that the patient wants to watch, such as nature and seaside walks, underwater videos, with music background, through virtual reality glasses for 10 minutes.

No Intervention: Control group

Patients will not use virtual reality glasses during trigger point injection.

Outcome Measures

Primary Outcome Measures

  1. State Anxiety Scale [10 minutes after procedure]

    The scale developed by Spielberger et al. aims to measure state and trait anxiety levels separately.The scores obtained from the scale vary between 20-80, and the total score between 20-39 indicates mild anxiety, between 40-59 indicates moderate anxiety, and between 60-79 indicates severe anxiety.

  2. General Comfort Scale [10 minutes after procedure]

    The scale, which was developed by Kolcaba in 2006 and has a total of 28 questions as 'Refreshing (9 items), Relaxation (9 items) and Overcoming Problems (10 items), consists of three sub-dimensions.The lowest value that can be taken is 1, which indicates low comfort, and the highest value, 6, indicates high comfort.

  3. Visual Analog Scale [In the middle (10 minutes) of the procedure]

    It is aimed to determine the level of pain.0 means no pain and 10 means maximum pain

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • The procedure will be applied for the first time

  • 18 years and over

  • Able to understand and speak Turkish

  • Able to understand verbal and written information given

  • Having good cognitive abilities

  • Without visual or hearing loss

  • Patients who agreed to participate in the study

Exclusion Criteria:
  • Those who do not understand or speak Turkish

  • Does not understand verbal and written information

  • Those with impaired cognitive abilities

  • Epilepsy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Elif Günay İsmailoğlu İzmir Menemen Turkey 35160

Sponsors and Collaborators

  • Izmir Bakircay University

Investigators

  • Principal Investigator: Elif Günay İsmailoğlu, Izmir Bakircay University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Elif Günay İsmailoğlu, Associate Professor, Izmir Bakircay University
ClinicalTrials.gov Identifier:
NCT06140368
Other Study ID Numbers:
  • BU-SBF-EI-003
First Posted:
Nov 20, 2023
Last Update Posted:
Nov 20, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Elif Günay İsmailoğlu, Associate Professor, Izmir Bakircay University

Study Results

No Results Posted as of Nov 20, 2023